{"pmid":32292227,"pmcid":"PMC7151242","title":"[Controversy regarding ACE inhibitors / ARBs in Covid-19].","text":["[Controversy regarding ACE inhibitors / ARBs in Covid-19].","Rev Esp Cardiol","Soria Arcos, Federico","Romero-Puche, Antonio","Vicente Vera, Tomas","32292227"],"journal":"Rev Esp Cardiol","authors":["Soria Arcos, Federico","Romero-Puche, Antonio","Vicente Vera, Tomas"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292227","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.recesp.2020.03.014","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664266295820943360,"score":8.233237,"similar":[{"pmid":32250244,"title":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.","text":["Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.","The discovery that SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) RNA binds to the angiotensin converting enzyme (ACE)-2, which is highly expressed in the lower airways, explained why SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) and respiratory failure. After this, news spread that ACEis and ARBs would be harmful in SARS-CoV-2-infected subjects. To the contrary, compelling evidence exists that the ACE-1/angiotensin(Ang)II/ATR-1 pathway is involved in SARS-CoV-2-induced ARDS, while the ACE-2/Ang(1-7)/ATR2/MasR pathway counteracts the harmful actions of AngII in the lung. A reduced ACE-1/ACE-2 ratio is, in fact, a feature of ARDS that can be rescued by human recombinant ACE-2 and Ang(1-7) administration, thus preventing SARS-CoV-2-induced damage to the lung. Based on the current clinical evidence treatment with ACE-inhibitors I (ACEis) or angiotensin receptor blockers (ARBs) continues to provide cardiovascular and renal protection in patients diagnosed with COVID-19. Discontinuing these medications may therefore be potentially harmful in this patient population.","Elife","Rossi, Gian Paolo","Sanga, Viola","Barton, Matthias","32250244"],"abstract":["The discovery that SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) RNA binds to the angiotensin converting enzyme (ACE)-2, which is highly expressed in the lower airways, explained why SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) and respiratory failure. After this, news spread that ACEis and ARBs would be harmful in SARS-CoV-2-infected subjects. To the contrary, compelling evidence exists that the ACE-1/angiotensin(Ang)II/ATR-1 pathway is involved in SARS-CoV-2-induced ARDS, while the ACE-2/Ang(1-7)/ATR2/MasR pathway counteracts the harmful actions of AngII in the lung. A reduced ACE-1/ACE-2 ratio is, in fact, a feature of ARDS that can be rescued by human recombinant ACE-2 and Ang(1-7) administration, thus preventing SARS-CoV-2-induced damage to the lung. Based on the current clinical evidence treatment with ACE-inhibitors I (ACEis) or angiotensin receptor blockers (ARBs) continues to provide cardiovascular and renal protection in patients diagnosed with COVID-19. Discontinuing these medications may therefore be potentially harmful in this patient population."],"journal":"Elife","authors":["Rossi, Gian Paolo","Sanga, Viola","Barton, Matthias"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250244","week":"202015|Apr 06 - Apr 12","doi":"10.7554/eLife.57278","keywords":["epidemiology","global health","viruses"],"source":"PubMed","locations":["ACE-1","AngII"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352136227880961,"score":128.54686},{"pmid":32268374,"title":"Keep Taking Your ACE Inhibitors and ARBs During the COVID 19 Pandemic.","text":["Keep Taking Your ACE Inhibitors and ARBs During the COVID 19 Pandemic.","J Travel Med","Speth, Robert C","32268374"],"journal":"J Travel Med","authors":["Speth, Robert C"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32268374","week":"202015|Apr 06 - Apr 12","doi":"10.1093/jtm/taaa045","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663609715757678593,"score":123.02465},{"pmid":32212881,"pmcid":"PMC7117596","title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","text":["Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.","Immunotherapy","Bersanelli, Melissa","32212881"],"journal":"Immunotherapy","authors":["Bersanelli, Melissa"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32212881","week":"202013|Mar 23 - Mar 29","doi":"10.2217/imt-2020-0067","keywords":["anti-CTLA-4","COVID-19","SARS-CoV-2","anti-PD-1","anti-PD-L1","cancer patients","immune checkpoint inhibitors","immunotherapy","tocilizumab","viral infection"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1663352135006289921,"score":93.5945},{"pmid":32239628,"title":"Coronavirus disease 2019 (COVID-19): facts and controversies.","text":["Coronavirus disease 2019 (COVID-19): facts and controversies.","Dermatol Ther","Conforti, Claudio","Cannavo, Serafinella Patrizia","Jafferany, Mohammad","Dianzani, Caterina","Meo, Nicola Di","Lotti, Torello","Zalaudek, Iris","Giuffrida, Roberta","32239628"],"journal":"Dermatol Ther","authors":["Conforti, Claudio","Cannavo, Serafinella Patrizia","Jafferany, Mohammad","Dianzani, Caterina","Meo, Nicola Di","Lotti, Torello","Zalaudek, Iris","Giuffrida, Roberta"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32239628","week":"202014|Mar 30 - Apr 05","doi":"10.1111/dth.13366","source":"PubMed","topics":["Mechanism","Transmission","Treatment"],"weight":1,"_version_":1663352135444594688,"score":74.49257},{"pmid":32303915,"title":"Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?","text":["Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?","Drug Saf","Trifiro, Gianluca","Crisafulli, Salvatore","Ando, Giuseppe","Racagni, Giorgio","Drago, Filippo","32303915"],"journal":"Drug Saf","authors":["Trifiro, Gianluca","Crisafulli, Salvatore","Ando, Giuseppe","Racagni, Giorgio","Drago, Filippo"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303915","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s40264-020-00935-2","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664431720414314496,"score":72.185265}]}